RxDoctor Payments Data

Joel Pelavin

Ophthalmology · Saint Clair Shores, MINPI 1881654655

Payments from drug & device makers

$556in general payments, 2019–2025

Across 25 payments — averaging $22.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$221
  • Alcon$62
  • Rxsight Inc$55
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$37
  • Bausch & Lomb Americas Inc.$36
  • Mallinckrodt Enterprises LLC$34
  • plus $111 from 5 others

What the payments were for

  • Food & beverage$556100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$556 in reported general payments places this provider in the 35th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$82,356
Medicare patients
347
Services billed
1,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost67$33,532
Latanoprost213$5,496
Brimonidine Tartrate26$5,347
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat127$4,058
Bimatoprost17$2,239
Timolol Maleate83$1,628
Fluorometholone19$1,517
ErythromycinErythromycin Base55$798
Acetazolamide11$708
Travoprost11$664
ValacyclovirValacyclovir Hcl12$294
MoxifloxacinMoxifloxacin Hcl21$286
Azithromycin16$51

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$221$33,53267 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Saint Clair Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →